Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure regarding its pharmaceutical contract manufacturing agreement with F.Hoffmann-La Roche Ltd, increasing the contract amount to approx. KRW 241.4B (USD 219,380,393) and extending the contract end date to December 31, 2028.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: (Correction) Single Sales and Supply Contract
- Original Filing Date: January 15, 2021
- Reason for Correction: Changes in contract amount and period upon customer request
- Key Correction Items:
- Contract Amount: (Before) KRW 234,432,963,608 ➔ (After) KRW 241,384,246,418
- Contract Amount to Revenue Ratio: (Before) 33.41% ➔ (After) 34.41%
- Contract End Date: (Before) December 31, 2027 ➔ (After) December 31, 2028
- Contract Details (As Revised in Filing):
- Contract Classification & Title: Other Sales/Supply Contract (Pharmaceutical Contract Manufacturing Agreement)
- Contract Amount: KRW 241,384,246,418 (USD 219,380,393, applied exchange rate KRW 1,100.30 per USD on initial disclosure date Jan 15, 2021)
- Recent Annual Revenue: KRW 701,591,859,755 (Based on recent annual revenue at initial disclosure)
- Contract Amount to Revenue Ratio: 34.41%
- Counterparty: F.Hoffmann-La Roche Ltd
- Contract Period: June 1, 2020 – December 31, 2028
- Contract Date: May 13, 2021
- Disclosure Postponement Details: Not applicable (-)
- Other Important Details:
- This contract is a definitive drug substance manufacturing agreement under the ‘Major Management Matters Related to Investment Decisions’ disclosed on June 8, 2020.
- The contract amount reflects an increase of USD 6,317,625 from the previously disclosed amount (USD 213,062,767.98) to USD 219,380,393.
- The contract end date is subject to change upon mutual agreement.
- Related Disclosures:
- June 08, 2020: Major Management Matters Related to Investment Decisions
- January 15, 2021: Single Sales and Supply Contract
- June 05, 2023: Single Sales and Supply Contract
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Contract Amount Increase and Period Extension
This correction disclosure provides notice that the contract amount for the pharmaceutical contract manufacturing deal with F.Hoffmann-La Roche Ltd has been increased by USD 6,317,625, with the contract period extended to December 31, 2028, at the client’s request.
Tracking contract execution progress and monitoring potential further updates to contract terms is essential.
Relevant developments can be verified in subsequent official disclosures and periodic filings.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
